PL3210981T3 - Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego - Google Patents

Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego

Info

Publication number
PL3210981T3
PL3210981T3 PL17164740T PL17164740T PL3210981T3 PL 3210981 T3 PL3210981 T3 PL 3210981T3 PL 17164740 T PL17164740 T PL 17164740T PL 17164740 T PL17164740 T PL 17164740T PL 3210981 T3 PL3210981 T3 PL 3210981T3
Authority
PL
Poland
Prior art keywords
beta
agonist activity
diamide compounds
receptor antagonist
receptor agonist
Prior art date
Application number
PL17164740T
Other languages
English (en)
Inventor
Adam Hughes
Daniel Byun
Yan Chen
Melissa Fleury
John Jacobsen
Eric Stangeland
Richard Wilson
Rose Yen
Original Assignee
Theravance Respiratory Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3210981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Respiratory Company, Llc filed Critical Theravance Respiratory Company, Llc
Publication of PL3210981T3 publication Critical patent/PL3210981T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
PL17164740T 2009-04-23 2010-04-16 Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego PL3210981T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23
EP17164740.7A EP3210981B1 (en) 2009-04-23 2010-04-16 Diamide compounds having muscarinic receptor antagonist and beta 2 adrenergic receptor agonist activity
EP10715058A EP2421849B1 (en) 2009-04-23 2010-04-16 Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP13151470.5A EP2599778B1 (en) 2009-04-23 2010-04-16 Diamide Compounds having Muscarinic Receptor Antagonist and Beta 2 Adrenergic Receptor Agonist Activity
PCT/US2010/031356 WO2010123766A1 (en) 2009-04-23 2010-04-16 DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (1)

Publication Number Publication Date
PL3210981T3 true PL3210981T3 (pl) 2019-06-28

Family

ID=42272140

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13151470T PL2599778T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
PL10715058T PL2421849T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2
PL17164740T PL3210981T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL13151470T PL2599778T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
PL10715058T PL2421849T3 (pl) 2009-04-23 2010-04-16 Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2

Country Status (32)

Country Link
US (14) US8138345B2 (pl)
EP (3) EP3210981B1 (pl)
JP (3) JP5671006B2 (pl)
KR (1) KR101769061B1 (pl)
CN (2) CN103936716B (pl)
AR (1) AR076412A1 (pl)
AU (1) AU2010239522B2 (pl)
BR (1) BRPI1014877B8 (pl)
CA (1) CA2758505C (pl)
CL (1) CL2011002637A1 (pl)
CO (1) CO6440584A2 (pl)
CY (2) CY1119008T1 (pl)
DK (3) DK2599778T3 (pl)
ES (3) ES2635358T3 (pl)
HK (1) HK1165799A1 (pl)
HR (3) HRP20130468T1 (pl)
HU (2) HUE035049T2 (pl)
IL (1) IL215554A (pl)
LT (2) LT2599778T (pl)
MX (1) MX2011011156A (pl)
MY (1) MY158339A (pl)
NZ (1) NZ595850A (pl)
PL (3) PL2599778T3 (pl)
PT (3) PT2421849E (pl)
RU (2) RU2543716C2 (pl)
SG (1) SG175330A1 (pl)
SI (3) SI2421849T1 (pl)
SM (1) SMT201300060B (pl)
TR (1) TR201903556T4 (pl)
TW (2) TWI570115B (pl)
WO (1) WO2010123766A1 (pl)
ZA (1) ZA201107743B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158339A (en) 2009-04-23 2016-09-30 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
KR101944564B1 (ko) 2011-06-10 2019-01-31 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
CA2838777C (en) 2011-06-10 2019-04-30 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
RU2661877C2 (ru) 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
JP6421989B2 (ja) 2012-12-06 2018-11-14 チエシ ファルマスティスィ エス．ピー．エー． ムスカリン受容体アンタゴニストおよびβ２アドレナリン受容体アゴニスト活性を有する化合物
PE20151414A1 (es) 2012-12-18 2015-09-17 Almirall Sa NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107108562B (zh) * 2015-05-14 2020-07-10 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
TW201704211A (zh) * 2015-05-14 2017-02-01 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的聯苯衍生物及其在醫藥上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
EP3383867B1 (en) 2015-12-03 2021-04-14 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112018015018A2 (pt) * 2016-01-22 2018-12-18 Sichuan Haisco Pharmaceutical Co Ltd derivado de amido azaciclo, método de preparação deste, e aplicação farmacêutica
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
RU2722720C1 (ru) 2016-12-14 2020-06-03 Бейджинг Шоубай Фармасьютикэл Ко., Лтд. Класс бифункциональных соединений со структурой соли четвертичного аммония
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE60021282T2 (de) * 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
EP1463396A1 (en) * 2001-12-04 2004-09-29 TOKYO R&D CO., LTD. Power supply
ES2351392T3 (es) * 2003-02-14 2011-02-03 Theravance Inc Derivados bifenilo que tienen actividad agonista de receptores beta2-adrenérgicos y actividad antagonista de receptores muscarínicos.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2289691T3 (es) 2004-01-22 2008-02-01 Pfizer, Inc. Derivados de sulfonamida para el tratamiento de enfermedades.
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
EP1833822A2 (en) * 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1778626A1 (en) * 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
DK2007214T4 (da) 2006-02-08 2014-09-22 Fuji Oil Europe Spiselige produkter med lavt indhold af mættede og trans-umættede fedter
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
MY158339A (en) 2009-04-23 2016-09-30 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Also Published As

Publication number Publication date
TW201546057A (zh) 2015-12-16
PL2421849T3 (pl) 2013-08-30
US20100273755A1 (en) 2010-10-28
SI3210981T1 (sl) 2019-05-31
US20200165223A1 (en) 2020-05-28
HRP20170960T1 (hr) 2017-09-22
EP2599778B1 (en) 2017-04-12
CL2011002637A1 (es) 2012-04-27
US8551978B2 (en) 2013-10-08
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
TR201903556T4 (tr) 2019-04-22
JP5965440B2 (ja) 2016-08-03
US9394275B2 (en) 2016-07-19
JP2015147807A (ja) 2015-08-20
BRPI1014877B1 (pt) 2020-11-10
WO2010123766A1 (en) 2010-10-28
US10358433B2 (en) 2019-07-23
DK2599778T3 (en) 2017-06-26
US20150274697A1 (en) 2015-10-01
US10836744B2 (en) 2020-11-17
MY158339A (en) 2016-09-30
US20170096412A1 (en) 2017-04-06
AU2010239522B2 (en) 2015-07-02
SI2421849T1 (sl) 2013-07-31
JP5671006B2 (ja) 2015-02-18
TWI513693B (zh) 2015-12-21
RU2015101032A (ru) 2015-06-27
RU2011147374A (ru) 2013-05-27
IL215554A (en) 2014-08-31
SG175330A1 (en) 2011-11-28
NZ595850A (en) 2013-05-31
IL215554A0 (en) 2011-12-29
KR20110138292A (ko) 2011-12-26
ES2635358T3 (es) 2017-10-03
TW201041866A (en) 2010-12-01
US20140323733A1 (en) 2014-10-30
BRPI1014877A2 (pt) 2016-04-12
US8138345B2 (en) 2012-03-20
CN103936716A (zh) 2014-07-23
DK3210981T3 (en) 2019-04-01
US9682957B2 (en) 2017-06-20
US20170226082A1 (en) 2017-08-10
SI2599778T1 (sl) 2017-08-31
KR101769061B1 (ko) 2017-08-17
CN102405218B (zh) 2014-06-04
BRPI1014877B8 (pt) 2021-05-25
CY1121601T1 (el) 2020-05-29
AR076412A1 (es) 2011-06-08
EP2421849B1 (en) 2013-04-03
HRP20190417T1 (hr) 2019-04-19
HRP20130468T1 (en) 2013-06-30
CO6440584A2 (es) 2012-05-15
US20190300504A1 (en) 2019-10-03
US10590107B2 (en) 2020-03-17
CA2758505C (en) 2017-03-07
EP3210981A1 (en) 2017-08-30
US20160361304A1 (en) 2016-12-15
US10138220B1 (en) 2018-11-27
US20130331364A1 (en) 2013-12-12
JP2014210816A (ja) 2014-11-13
US20130137665A1 (en) 2013-05-30
ES2715965T3 (es) 2019-06-07
MX2011011156A (es) 2011-11-04
EP2599778A1 (en) 2013-06-05
ZA201107743B (en) 2012-06-27
PT3210981T (pt) 2019-04-01
CY1119008T1 (el) 2018-01-10
HUE042975T2 (hu) 2019-07-29
US9000173B2 (en) 2015-04-07
EP3210981B1 (en) 2019-01-02
JP2012524783A (ja) 2012-10-18
LT3210981T (lt) 2019-04-10
LT2599778T (lt) 2017-08-25
CN102405218A (zh) 2012-04-04
ES2417339T3 (es) 2013-08-07
US20210024493A1 (en) 2021-01-28
US9975875B2 (en) 2018-05-22
EP2421849A1 (en) 2012-02-29
HK1165799A1 (en) 2012-10-12
US20170362200A1 (en) 2017-12-21
TWI570115B (zh) 2017-02-11
SMT201300060B (it) 2013-07-09
PT2599778T (pt) 2017-06-06
CA2758505A1 (en) 2010-10-28
PT2421849E (pt) 2013-05-27
US20190047984A1 (en) 2019-02-14
DK2421849T3 (da) 2013-07-01
BRPI1014877A8 (pt) 2018-03-13
CN103936716B (zh) 2016-09-07
RU2015101032A3 (pl) 2018-07-30
RU2543716C2 (ru) 2015-03-10
HUE035049T2 (en) 2018-05-02
PL2599778T3 (pl) 2018-01-31
RU2676686C2 (ru) 2019-01-10
AU2010239522A1 (en) 2011-11-10
US9771350B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
HRP20190417T1 (hr) Diamidni spojevi s aktivnošću antagonista muskarinskog receptora i agonista beta 2 adrenergičkog receptora
HK1212989A1 (zh) 具有毒蕈鹼受體拮抗劑和β 腎上腺素能受體激動劑活性的化合物
ZA201309242B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HK1212987A1 (zh) 具有毒蕈鹼受體拮抗劑和β 腎上腺素能受體激動劑活性的化合物
EP2120575A4 (en) AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
HK1197240A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities 2 m3
IL232477A (en) Cyclohexylamine derivatives with the activity of beta 2-adrenergic agonist and 3m muscarinic antagonist
ZA201202520B (en) Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
ZA200808817B (en) Dialkylphenyl compounds having ß2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ZA200903873B (en) Sphingosine-1-phosphate receptor agonist and antagonist compounds